Short answer
Vericel Corp (VCEL) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $68M (up 16.6% year over year) with net income of $5M.
Q3 2025 key financials · XBRL
- Revenue
- $68M
- +16.6% YoY · +6.7% QoQ
- Net income
- $5M
- +663.2% YoY · +1017.5% QoQ
- Operating margin
- 5.1%
- Gross margin
- 73.5%
- EPS (diluted)
- $0.11
- +1200.0% YoY · +1200.0% QoQ
Source: XBRL data from the Vericel Corp (VCEL) Q3 2025 10-Q on SEC EDGAR. USD.
Vericel Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New FDA operational risk from 2025 federal employee layoffs affecting review of MACI Ankle IND and clinical trial enrollment start in H2 2025
- Most material update: disruptions and leadership resignations at FDA causing potential delays in inspections and approvals of manufacturing facilities
- Regulatory risk: new Trump administration executive orders and creation of Department of Government Efficiency could reduce FDA funding and increase approval delays
- Operational risk: uncertainty from 2025 presidential administration change may alter FDA policies, affecting speed and likelihood of product approvals
- Financial risk from government budget unpredictability threatening funding for FDA and agencies critical to product development and regulatory review
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Vericel Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.